Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS 2 articles
March 17, 2008
- Korosho Hears Major Pharmacy Chain Operators
March 17, 2008
- Quintiles Embarks on HMS Business
March 17, 2008
- Claritin Ranked No. 1 in January in Rep Track Survey
March 17, 2008
- NHI Prices Down 10% for ARBs and SSRIs
March 17, 2008
- Most Doctors Don't Like Cravit to Be Replaced with Generics
March 17, 2008
- GENERICS NEWS IN BRIEF
March 17, 2008
- Chugai Actively Participates in Collaborative Multinational Studies
March 17, 2008
- REGULATORY NEWS IN BRIEF
March 17, 2008
- Successor of Iressa in PIII: AstraZeneca
March 17, 2008
- Mylan to Provide Generics Needed at Clinical Settings: Mr Coury
March 17, 2008
- R&D NEWS IN BRIEF
March 17, 2008
- Generics Save Money: St. Marianna Univ. Hospital
March 17, 2008
- Switching Nicotinell TTS to OTC Status Recommended
March 17, 2008
- Eisai Aims at \1.5 Trillion Sales in FY2016
March 17, 2008
- SELF-MEDICATION NEWS IN BRIEF
March 17, 2008
- Kyowa Hakko Licenses KW-8761 to Amgen
March 17, 2008
- Correct Diagnosis of Pompe Disease Is Important: Dr Kawai
March 17, 2008
- Alfresa Directly Enters Kyushu Market
March 10, 2008
- Toledomin's Initial Dose to Be Changed Following Reexamination
March 10, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…